CAM
AGIO icon

Connacht Asset Management’s Agios Pharmaceuticals AGIO Stock Holding History

Connacht Asset Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-9,648
Closed -$281K – 154
2022
Q1 		$281K Buy
9,648
+2,515
+35% +$76.8K 0.14% 109
2021
Q4 		$234K Buy
+7,133
New +$287K 0.23% 92

Other funds holding AGIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Connacht Asset Management's AGIO Position: Q2 2022 in Review

Connacht Asset Management sold out of Agios Pharmaceuticals (AGIO) in Q2 2022, closing a stake of 9,648 shares — an estimated $281K sold.

Connacht Asset Management first reported a position in AGIO in Q4 2021 and held it in 2 quarters. The position peaked at $281K in Q1 2022. 156 funds tracked by Wall St. Rank hold AGIO as of Q2 2022.

  • Connacht Asset Management reported no remaining Agios Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Connacht Asset Management sold 9,648 Agios Pharmaceuticals shares in Q2 2022, an estimated $281K.
  • Connacht Asset Management first reported a position in Agios Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Connacht Asset Management's Agios Pharmaceuticals position peaked at $281K in Q1 2022.
  • 156 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2022.

Based on Connacht Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.